28 November 2018 | News
Emdolten is positioned to become a preferred first line ARV.
Image credit- cdc.gov
Aspen Pharmacare, South Africa’s leading JSE-listed pharmaceutical company, is pleased to announce the launch of Emdolten, a Dolutegravir-based triple combination anti-retroviral (ARV) treatment option.
Emdolten, a once a day triple combination tablet therapy in the form of Dolutegravir, Lamivudine and Tenofovir Disoproxil Fumarate, is positioned to become a preferred first line ARV and will be available in 50mg, 300mg/300mg dosage strengths.
Aspen’s pioneering efforts resulted in the accelerated introduction of South Africa’s public ARV programme which has contributed to the successful treatment of hundreds of thousands of patients afflicted with HIV and AIDS.